

Paul Stang, PhD is currently Senior Director of Epidemiology for Johnson & Johnson. Prior to joining J&J, Dr. Stang was a Vice-President at Cerner Corporation, which he joined after co-founding and serving as the Chief Scientific Officer of Galt Associates, a health care consulting and informatics start-up that was purchased by Cerner. He has worked as a college professor, and has held leadership positions of increasing responsibility in outcomes and epidemiology groups at Glaxo and SmithKline Beecham. Currently, Paul also serves as a co-Principal Investigator for the Foundation for the National Institutes of Health's Observational Medical Outcomes Partnership (OMOP), a public-private partnership whose aim is to design a series of investigations to objectively assess the performance, value and impact of observational data in monitoring the safety and benefit of medications. Dr. Stang also serves on the scientific consulting staff of the eHI Collaboration Connecting Communities for Drug Safety Collaboration.

Dr. Stang has published widely in epidemiology, health outcomes, productivity, and communications with over 150 journal articles, abstracts, book chapters, and books including *Health and Work Productivity: Making the Business Case for Quality Healthcare* with University of Chicago Press. He was also an author of the Methods and Design chapter in *Registries for Evaluating Patient Outcomes: A User's Guide* (Agency for Healthcare Quality and Research, May 2007). He continues to serve as a reviewer for a number of journals and is a member of a number of research consortia including the World Mental Health Initiative.

Dr Stang received his BA from University of NC at Chapel Hill in Embryology and Genetics, Physician Assistant certification from the Bowman Gray School of Medicine, MS in Health Sciences Research from SUNY-Stony Brook, and PhD in Public Health-Epidemiology from the University of NC at Chapel Hill. He practiced as a Physician Associate focused primarily in Neurology and Neurosurgery for 9 years, and still retains adjunct faculty appointments at several institutions. He was elected a Fellow in 2004 to the International Society for Pharmacoepidemiology.